• The risk of heart problems is affected by your dose, medical history (including previous heart disease , radiation treatment to the chest area, or if you have MS- multiple sclerosis ), and previous use of this and other drugs (including doxorubicin or daunorubicin ). (webmd.com)
  • Tell your doctor and pharmacist if you are taking or have ever received certain cancer chemotherapy medications such as daunorubicin (Cerubidine), doxorubicin (Doxil), epirubicin (Ellence), or idarubicin (Idamycin), or if you have ever been treated with mitoxantrone in the past. (medlineplus.gov)
  • In a study by Fernandez et al, 657 patients younger than 60 years with untreated AML received either conventional-dose daunorubicin (45 mg/m 2 /d for 3 d) or high-dose daunorubicin (90 mg/m 2 /d for 3 d). (medscape.com)
  • A higher rate of complete remission was observed in the high-dose daunorubicin group (70.6%) relative to the conventional dose (57.3%) as well as an improved overall survival (median, 23.7 mo) compared with the group administered the conventional dose (15.7 mo). (medscape.com)
  • In a similar study in patients 60 years of age or older by Lowenberg et al, 813 patients received either conventional-dose treatment (daunorubicin 45 mg/m 2 /d for 3 d) or escalated-dose treatment (daunorubicin 90 mg/m 2 /d for 3 d), both administered over 3 hours on days 1, 2, and 3. (medscape.com)
  • Alternatively, high-dose cytarabine combined with idarubicin, daunorubicin, or mitoxantrone can be used as induction therapy in younger patients. (medscape.com)
  • The two main drugs are cytarabine and daunorubicin, but others such as idarubicin, mitoxantrone and etoposide can be used. (technologynetworks.com)
  • The recommended dose of epirubicin varies widely according to the specific condition being treated, the response to therapy, the other medications being used, and the body size of the recipient person receiving treatment. (medbroadcast.com)
  • Mitoxantrone is an immunosuppressant drug approved by the FDA for treatment of several forms of advancing MS. It is one of only two drugs that has been shown to benefit people with secondary progressive MS who are having attacks. (scienceblog.com)
  • These immunomodulators are now a first-line treatment of relapsing-remitting (RR) and relapsing-progressive (RP) MS. In 2000, mitoxantrone - a cytolytic immunosuppressant - was approved for the treatment of patients with a rapidly progressive disease. (touchneurology.com)
  • Read the Medication Guide provided by your pharmacist before you start receiving mitoxantrone and each time you get a refill. (webmd.com)
  • The risk of heart damage may depend on the total amount of mitoxantrone given to a person over a lifetime, so your doctor will probably limit the total number of doses you receive if you are using this medication for MS. If you experience any of the following symptoms, call your doctor immediately: difficulty breathing, chest pain, swelling of the legs or ankles, or irregular or fast heartbeat. (medlineplus.gov)
  • When mitoxantrone injection is used to treat leukemia, you will continue to receive this medication based on your condition and how you respond to the treatment. (medlineplus.gov)
  • Many things can affect the dose of a medication that a person needs, such as body weight, other medical conditions, and other medications. (medbroadcast.com)
  • A side effect is an unwanted response to a medication when it is taken in normal doses. (medbroadcast.com)
  • Some dosing schedules call for smaller doses of the medication to be administered for 3 consecutive days every 4 weeks. (pharmasave.com)
  • Include each medication, the dose, and how many times you take it per day. (life-in-spite-of-ms.com)
  • Mitoxantrone can cause nausea and vomiting, but it is important to keep using this medication even if you feel ill. (mediresource.com)
  • METHODS: In the randomized, double-blind, time-to-event, phase 3 PREVENT trial, 143 adults received eculizumab (maintenance dose, 1200 mg/2 weeks) or placebo (2:1), with stable-dose concomitant immunosuppressive therapy (IST) permitted (except rituximab and mitoxantrone). (ox.ac.uk)
  • The addition of mitoxantrone (Novantrone) to interferon beta-1b (IFN beta-1b, Betaseron) therapy for the treatment of patients with aggressive multiple sclerosis (MS) unresponsive to standard therapy may reduce the number of new enhancing lesions as well as life-threatening risks associated with mitoxantrone therapy. (psychiatrictimes.com)
  • Some dosing schedules suggest that smaller doses be given on a weekly basis. (medbroadcast.com)
  • Mitoxantrone should be given only under the supervision of a doctor with experience in the use of chemotherapy medications. (medlineplus.gov)
  • Mitoxantrone may increase your risk for developing leukemia (cancer of the white blood cells), especially when it is given in high doses or together with certain other chemotherapy medications. (medlineplus.gov)
  • Mitoxantrone injection is also used together with steroid medications to relieve pain in people with advanced prostate cancer who did not respond to other medications. (medlineplus.gov)
  • Mitoxantrone injection is also used with other medications to treat certain types of leukemia. (medlineplus.gov)
  • Mitoxantrone injection is in a class of medications called anthracenediones. (medlineplus.gov)
  • Your doctor may need to change the doses of your medications or monitor you carefully for side effects. (safemedication.com)
  • Doses are usually given at 3- to 4-week intervals, either alone or with other medications used to treat cancer. (medbroadcast.com)
  • Administration of high doses of intravenous corticosteroids, such as methylprednisolone, is the routine therapy for acute relapses. (wikipedia.org)
  • Mitoxantrone is used to treat leukemia and other cancers. (webmd.com)
  • Those studies showed that acute leukemia occurred in .07 percent to .25 percent of MS patients taking mitoxantrone. (scienceblog.com)
  • The potential risk of leukemia should be carefully considered against the potential benefits of mitoxantrone treatment on every single patient. (scienceblog.com)
  • It is vital that all MS patients treated with mitoxantrone undergo prolonged and careful hematological follow-up to check for acute leukemia," Martinelli said. (scienceblog.com)
  • One of the drawbacks of mitoxantrone-and it has several-is that once a cumulative dose of 140 mg/m 2 has been reached, risk of leukemia and cardiotoxicity in the form of congestive heart failure emerges. (psychiatrictimes.com)
  • This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). (rochester.edu)
  • High doses of alkylating agents can potentially damage bone marrow, which can lead to leukemia . (healthline.com)
  • High doses of mitotic inhibitors can cause nerve damage. (healthline.com)
  • The FDA has warned that the risk of myocardial infarction or stroke can occur as early as the first weeks of using a NSAID, and risk may increase with higher doses and longer duration of use. (pdr.net)
  • A benefit of higher doses has been found with IFNβ 1b (500 versus 250μg) and IFNβ 1a sc (44 versus 22μg). (touchneurology.com)
  • Mitoxantrone-based combinations are a standard palliative treatment in hormone-refractory prostate cancer (HRPC) but with no survival benefit. (ingentaconnect.com)
  • Mitoxantrone treats MS by stopping certain cells of the immune system from reaching the brain and spinal cord and causing damage. (medlineplus.gov)
  • Mitoxantrone is an immunosuppressive drug for worsening forms of MS, and it has been shown to extend the time between relapses. (psychiatrictimes.com)
  • Determine the safety and feasibility of this drug, in terms of incidence and maximum grade of toxicity and courses delayed or doses reduced, in these patients. (knowcancer.com)
  • For which cytotoxic drugs is renal damage the dose-limiting toxicity? (freezingblue.com)
  • In reproductive studies in rats and rabbits, pamidronate doses equivalent to 0.6 to 8.3 times the highest human recommended dose resulted in maternal toxicity and embryo/fetal effects. (sdrugs.com)
  • the ATO dosage is 0.15 mg/kg/day IV until bone marrow remission occurs (maximum induction, 60 doses). (medscape.com)
  • When the patients did not achieve a complete remission at the end of the induction of the COAP protocol or when a loss of remission happens during the LMP, generally the addition of vincristine every two weeks to the LMP protocol in a dose of 0.5 mg/m 2 alternated with the chlorambucil is enough to reinduce and maintain a remission. (vin.com)
  • However, 2 studies demonstrated improved disease-free survival rates in younger patients who received high-dose cytarabine during induction. (medscape.com)
  • If a complete remission is achieved when a rescue protocol is started, the dose of the asparaginase may be "saved" for the future, but if only a partial remission is obtained, intensification with asparaginase may be necessary). (vin.com)
  • The complete remission rate was 64% in the escalated-dose group compared with 54% in conventional-dose group. (medscape.com)
  • Our study presented for the first time an active loading method for imatinib and suggests that the optimized liposomal formulation co-encapsulates both drugs with high encapsulation efficiency (>95%), shows enhanced drug retention under tested conditions and delivers a drug:drug ratio capable of improving tumor cell growth inhibition with a mitoxantrone dose reduction of 2.6-fold as compared to single liposomal formulation. (ingentaconnect.com)
  • When we added mitoxantrone to the therapeutic regimen of patients who were breaking through with IFN beta-1b, the disease activity measured by MRI in clinical parameters was remarkably diminished,' said Douglas Jeffery, MD, PhD, associate professor in neurology at Wake Forest University School of Medicine in Winston-Salem, North Carolina. (psychiatrictimes.com)
  • Both are given by intravenous infusion at monthly intervals in the case of natalizumab and every three months in the case of mitoxantrone. (wikipedia.org)
  • It is recommended not to initiate therapy with maximum doses in these patients due to the likely increase frequency of adverse reactions. (pdr.net)
  • The combination of IFN beta-1b and mitoxantrone reduces these adverse effects, which are associated with mitoxantrone therapy, while effectively suppressing MS-associated inflammation, explained Jeffery. (psychiatrictimes.com)
  • After mitoxantrone was added to the initial IFN beta-1b therapy, enhancing lesion frequency was reduced by an average of 90%, enhancing lesion volume decreased by 96%, and relapse rates decreased by 70% at month 7. (psychiatrictimes.com)
  • T2 lesion burden and T1 hypointense lesion burden increased slightly during the baseline phase and decreased after initiation of mitoxantrone therapy. (psychiatrictimes.com)
  • We use mitoxantrone in patients who have had an inadequate response to optimal immunomodulating therapy, whose MS is worsening, or in those who have extremely aggressive disease right from the onset,' said Jeffery. (psychiatrictimes.com)
  • Involved-site radiation therapy (ISRT) is typically recommended, because high-dose, large-field radiation therapy (LFRT) increases risk for heart disease, pulmonary dysfunction, and secondary cancers. (medscape.com)
  • Prior to initiating the dose expansion trial, the Company conducted a Phase 1b dose escalation trial. (aptevotherapeutics.com)
  • The dose escalation trial included 46 patients with AML or myelodysplastic syndrome (MDS). (aptevotherapeutics.com)
  • The study participants all had at least one cycle of mitoxantrone treatment and were observed for at least one year. (scienceblog.com)
  • The results of Jeffery's study suggest that a longer duration of treatment with mitoxantrone may result in a greater reduction in disease activity. (psychiatrictimes.com)
  • Mitoxantrone injection may cause damage to your heart at any time during your treatment or months to years after your treatment has ended. (medlineplus.gov)
  • Your doctor will examine you and perform certain tests to check how well your heart is working before beginning treatment with mitoxantrone and if you show any signs of heart problems. (medlineplus.gov)
  • and problems with vision, speech, and bladder control), your doctor will also perform certain tests before each dose of mitoxantrone injection and yearly after you have completed your treatment. (medlineplus.gov)
  • Your doctor will probably start you on a low dose of safinamide and may increase your dose once after at least 2 weeks of treatment. (safemedication.com)
  • Higher-than-conventional radiation doses in localized prostate cancer treatment: A meta-analysis of randomized, controlled trials. (sfu.ca)
  • Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. (mcmaster.ca)
  • Treatment with ONUREG ® at the doses recommended for intravenous or subcutaneous azacitidine may not be effective. (onuregpro.com)
  • Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. (sfu.ca)
  • 3 In contrast, a higher dose of IFNβ 1a im (60 versus 30μg) did not improve the benefit and led to a greater incidence of NAbs. (touchneurology.com)
  • The main aim of the work was to develop novel liposomal formulations comprising imatinib co-encapsulated with mitoxantrone, by different loading methods and experimental conditions, in order to achieve the highest drug loading and maximum physical stability. (ingentaconnect.com)
  • Due to this, the lifetime cumulative dose is equal to about eight to 12 doses over two to three years. (scienceblog.com)
  • They also had a greater cumulative dose of mitoxantrone. (scienceblog.com)
  • The lifetime cumulative dose is limited to 140 mg/m 2 (approximately 8 to 12 doses over 2 to 3 years). (psychiatrictimes.com)
  • extensive hepatic metab by xanthine oxidase, SO decr dose mercapto if taking xanthine oxidase inhibs (allopurinol, fubuxostat). (freezingblue.com)
  • When Jeffery and colleagues combined mitoxantrone and IFN beta-1b therapies, symptoms and disease activity substantially declined in patients participating in a pilot trial. (psychiatrictimes.com)
  • Our previous In Vitro studies demonstrated that simultaneous combination of imatinib with mitoxantrone yielded additive growth inhibition effects against PC-3 cell line. (ingentaconnect.com)
  • Patients treated with Pamidronate for bone metastases should have the dose withheld if renal function has deteriorated. (sdrugs.com)
  • High dose chemotherapy is sometimes followed by a stem cell or bone marrow transplant. (technologynetworks.com)
  • Mitoxantrone injection comes as a liquid to be given intravenously (into a vein) by a doctor or nurse in a hospital or clinic. (medlineplus.gov)
  • Due to substantial differences in the pharmacokinetic parameters, the recommended dose and schedule for ONUREG ® are different from those for the intravenous or subcutaneous azacitidine products. (onuregpro.com)
  • With the addition of vincristine to the LMP protocol, many cases achieve a long second remission time, but when a second loss of remission is present or if the increment in the vincristine dose was not enough to maintain the remission, a rescue protocol has to be started. (vin.com)
  • DUE TO THE RISK OF CLINICALLY SIGNIFICANT DETERIORATION IN RENAL FUNCTION, WHICH MAY PROGRESS TO RENAL FAILURE, SINGLE DOSES OF Pamidronate SHOULD NOT EXCEED 90 MG. Renal deterioration, progression to renal failure, and dialysis have been reported in patients after the initial or a single dose of Pamidronate. (sdrugs.com)